SFM
PTGX icon

Sphera Funds Management’s Protagonist Therapeutics PTGX Stock Holding History

Sphera Funds Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-250,000
Closed -$8.55M – 90
2021
Q4 		$8.55M Hold
250,000
– – 0.94% 34
2021
Q3 		$4.43M Buy
+250,000
New +$10.7M 0.37% 72

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Sphera Funds Management's PTGX Position: Q4 2021 in Review

Sphera Funds Management sold out of Protagonist Therapeutics (PTGX) in Q4 2021, closing a stake of 260,379 shares — an estimated $8.23M sold.

Sphera Funds Management first reported a position in PTGX in Q4 2019 and held it in 5 quarters. The position peaked at $13.6M in Q2 2021. 149 funds tracked by Wall St. Rank hold PTGX as of Q4 2021.

  • Sphera Funds Management reported no remaining Protagonist Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Sphera Funds Management sold 260,379 Protagonist Therapeutics shares in Q4 2021, an estimated $8.23M.
  • Sphera Funds Management first reported a position in Protagonist Therapeutics in Q4 2019 and held it in 5 quarters.
  • Sphera Funds Management's Protagonist Therapeutics position peaked at $13.6M in Q2 2021.
  • 149 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2021.

Based on Sphera Funds Management's 13F filing for Q4 2021, filed 14 Feb 2022.